Category: Boehringer Ingelheim
-
Boehringer wins PI against Dr. Reddy’s that blocks generic empagliflozin (Jardiance) sales in UK pending October 2026 trial: patent thickets work
In some jurisdictions it pays off for Boehringer Ingelheim to have created a patent thicket around empaglifozin (Jardiance) involving use and formulation patents.
-
Pharma patent litigation updates: Boehringer, Orion, Pfizer, Kaleo file fresh patent infringement suits in District of Delaware
The District of Delaware continues to receive a substantial volume of pharmaceutical patent infringement complaints, with an arthritis-related Pfizer suit and diabetes-related Boehringer suit among the latest.
-
Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national law
Context: Three months ago, the Unified Patent Court’s (UPC) Lisbon Local Division (LD) denied an application for provisional measures (which in some other jurisdictions would be called a motion for a preliminary injunction (PI)) by Boehringer Ingelheim against Zentiva, holding that an infringement did not appear imminent (item 2 of our May 10, 2025 UPC…